Literature DB >> 6085386

Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers.

J Kann, G J Krol, K D Raemsch, D E Burkholder, M J Levitt.   

Abstract

Relative bioavailability of 5-, 10-, and 20-mg nitrendipine tablets was determined in a four-way crossover bioequivalence study involving 22 normal male volunteers. Liquid suspension of nitrendipine was used as a reference. Plasma and urine samples collected during each study period were assayed by high performance liquid chromatographic and capillary gas chromatographic (GC) procedures for nitrendipine and the nitrendipine pyridine metabolite. Four other more polar urinary nitrendipine metabolites were also analyzed in urine by the GC procedure, which involved diazomethane esterification. Although relative bioavailability of the tablets ranged from 58.0 to 69.9%, there was no statistically significant difference in the area under the curve among the doses. Since 35 to 43% of both the liquid and tablet doses was recovered in the urine of volunteers, excretion of urinary metabolites appears to be independent of the dosage form. However, a rank-order correlation between the relative tablet bioavailability and cumulative amounts of excreted metabolites was observed. Nitrendipine, its pyridine metabolite, and the glucuronide conjugates were also detected in the urine, but the amount of nitrendipine and its pyridine metabolite did not exceed 0.1% of dose, whereas the glucuronides accounted for about 8% of the dose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6085386

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  16 in total

Review 1.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

2.  Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study.

Authors:  P A Soons; A G de Boer; P van Brummelen; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

3.  Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure.

Authors:  T Ankermann; U Osterkamp; S R Santos; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Plasma nitrendipine concentrations in elderly hypertensive patients after single and multiple dosing.

Authors:  P Crome; A Baksi; D MacMahon; N D Pandita-Gunawardena; J Edwards; J Marley
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

5.  Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration.

Authors:  G Mikus; C Fischer; B Heuer; C Langen; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

6.  Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.

Authors:  V Mast; C Fischer; G Mikus; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

7.  Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy.

Authors:  M R Lawrence; F Broughton Pipkin
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

Review 8.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

9.  Bioavailability and elimination of nitrendipine in liver disease.

Authors:  P Dylewicz; W Kirch; S R Santos; H J Hutt; H Mönig; E E Ohnhaus
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Scavenging of the one-electron reduction product from nisoldipine with relevant thiols: electrochemical and EPR spectroscopic evidences.

Authors:  L J Núñez-Vergara; G Díaz-Araya; C Olea-Azar; A M Atria; S Bollo-Dragnic; J A Squella
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.